Hans Edgar Bishop

Insider Reports History

Location: Seattle, WA
Owner filing signature: /s/ Aaron M. Grossman, Attorney-in-Fact for Hans Edgar Bishop
Transaction evidence: Report rows are grouped by the transaction date disclosed in the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Hans Edgar Bishop

Form 4 holding Director

Sana Biotechnology, Inc.

Security class: Common Stock
Shares / value: 5,848,503
Estimated value: $16,843,688
Report date: 06 Apr 2026
Price: $2.88
Ownership: Direct

Form 4 holding Director

Lyell Immunopharma, Inc.

Security class: Common Stock
Shares / value: 4,685,614
Estimated value: $10,683,200
Report date: 14 Jun 2024
Price: $2.28
Ownership: Direct

Form 4 holding Director

AGILENT TECHNOLOGIES, INC.

Security class: Common Stock
Shares / value: 24,976
Estimated value: $3,683,506
Report date: 15 Mar 2024
Price: $147.48
Ownership: Direct

Form 4 holding Director

Lyell Immunopharma, Inc.

Security class: Option (right to buy)
Shares / value: 130,000
Estimated value
Report date: 14 Jun 2024
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

Sana Biotechnology, Inc.

Security class: Stock Option (Right to Buy)
Shares / value: 80,000
Estimated value
Report date: 05 Jun 2025
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Insider Reports Filed by Hans Edgar Bishop

4 SANA

Sana Biotechnology, Inc.

Report period: 06 Apr 2026
Transactions: 1
Transaction value: $0
Accepted by SEC: 08 Apr 2026, 16:16
Role: Director
Next action: Open filing details

4 SANA

Sana Biotechnology, Inc.

Report period: 05 Jan 2026
Transactions: 1
Transaction value: $0
Accepted by SEC: 06 Jan 2026, 16:18
Role: Director
Next action: Open filing details

4 SANA

Sana Biotechnology, Inc.

Report period: 06 Oct 2025
Transactions: 1
Transaction value: $0
Accepted by SEC: 07 Oct 2025, 17:21
Role: Director
Next action: Open filing details

4 SANA

Sana Biotechnology, Inc.

Report period: 07 Jul 2025
Transactions: 1
Transaction value: $0
Accepted by SEC: 08 Jul 2025, 16:17
Role: Director
Next action: Open filing details

4 SANA

Sana Biotechnology, Inc.

Report period: 05 Jun 2025
Transactions: 1
Transaction value: $0
Accepted by SEC: 09 Jun 2025, 16:40
Role: Director
Next action: Open filing details

4 SANA

Sana Biotechnology, Inc.

Report period: 07 Apr 2025
Transactions: 1
Transaction value: $0
Accepted by SEC: 08 Apr 2025, 16:22
Role: Director
Next action: Open filing details

4 SANA

Sana Biotechnology, Inc.

Report period: 06 Jan 2025
Transactions: 1
Transaction value: $0
Accepted by SEC: 07 Jan 2025, 16:26
Role: Director
Next action: Open filing details

4 SANA

Sana Biotechnology, Inc.

Report period: 07 Oct 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 09 Oct 2024, 16:11
Role: Director
Next action: Open filing details

4 SANA

Sana Biotechnology, Inc.

Report period: 05 Jul 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 08 Jul 2024, 16:32
Role: Director
Next action: Open filing details

4 LYEL

Lyell Immunopharma, Inc.

Report period: 14 Jun 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 17 Jun 2024, 16:17
Role: Director
Next action: Open filing details

4/A SANA

Sana Biotechnology, Inc.

Report period: 06 Jun 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 15 Jul 2024, 16:09
Role: Director
Next action: Open filing details

4 SANA

Sana Biotechnology, Inc.

Report period: 06 Jun 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 07 Jun 2024, 16:21
Role: Director
Next action: Open filing details

4 SANA

Sana Biotechnology, Inc.

Report period: 05 Apr 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 08 Apr 2024, 16:51
Role: Director
Next action: Open filing details

4 A

AGILENT TECHNOLOGIES, INC.

Report period: 15 Mar 2024
Transactions: 2
Transaction value: +$358,081
Accepted by SEC: 19 Mar 2024, 18:18
Role: Director
Next action: Open filing details

4 SANA

Sana Biotechnology, Inc.

Report period: 05 Jan 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 08 Jan 2024, 17:38
Role: Director
Next action: Open filing details

4 SANA

Sana Biotechnology, Inc.

Report period: 05 Oct 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 06 Oct 2023, 16:20
Role: Director
Next action: Open filing details

4 LYEL

Lyell Immunopharma, Inc.

Report period: 08 Sep 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 08 Sep 2023, 16:20
Role: Director
Next action: Open filing details

4 SANA

Sana Biotechnology, Inc.

Report period: 05 Jul 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 06 Jul 2023, 16:21
Role: Director
Next action: Open filing details

4 LYEL

Lyell Immunopharma, Inc.

Report period: 16 Jun 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 20 Jun 2023, 16:40
Role: Director
Next action: Open filing details

4 SANA

Sana Biotechnology, Inc.

Report period: 08 Jun 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 09 Jun 2023, 16:30
Role: Director
Next action: Open filing details

4 SANA

Sana Biotechnology, Inc.

Report period: 05 Apr 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 06 Apr 2023, 16:45
Role: Director
Next action: Open filing details

4 A

AGILENT TECHNOLOGIES, INC.

Report period: 16 Mar 2023
Transactions: 2
Transaction value: +$328,231
Accepted by SEC: 20 Mar 2023, 21:38
Role: Director
Next action: Open filing details

4 SANA

Sana Biotechnology, Inc.

Report period: 05 Jan 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 06 Jan 2023, 15:17
Role: Director
Next action: Open filing details

4 SANA

Sana Biotechnology, Inc.

Report period: 05 Oct 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 06 Oct 2022, 16:05
Role: Director
Next action: Open filing details

4 LYEL

Lyell Immunopharma, Inc.

Report period: 08 Sep 2022
Transactions: 2
Transaction value: +$14,538
Accepted by SEC: 09 Sep 2022, 16:05
Role: Director
Next action: Open filing details

4 SANA

Sana Biotechnology, Inc.

Report period: 05 Jul 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 07 Jul 2022, 16:32
Role: Director
Next action: Open filing details

4 LYEL

Lyell Immunopharma, Inc.

Report period: 08 Jun 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 10 Jun 2022, 16:11
Role: Director
Next action: Open filing details

4 SANA

Sana Biotechnology, Inc.

Report period: 06 Jun 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 08 Jun 2022, 18:33
Role: Director
Next action: Open filing details

4 SANA

Sana Biotechnology, Inc.

Report period: 05 Apr 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 06 Apr 2022, 17:55
Role: Director
Next action: Open filing details

4 A

AGILENT TECHNOLOGIES, INC.

Report period: 17 Mar 2022
Transactions: 2
Transaction value: +$353,269
Accepted by SEC: 21 Mar 2022, 17:03
Role: Director
Next action: Open filing details

4 LYEL

Lyell Immunopharma, Inc.

Report period: 23 Feb 2022
Transactions: 2
Transaction value: +$99,343
Accepted by SEC: 25 Feb 2022, 15:05
Role: Director
Next action: Open filing details

4 LYEL

Lyell Immunopharma, Inc.

Report period: 21 Jun 2021
Transactions: 2
Transaction value: $0
Accepted by SEC: 23 Jun 2021, 17:35
Role: Director
Next action: Open filing details

3 LYEL

Lyell Immunopharma, Inc.

Report period: 16 Jun 2021
Transactions: 0
Transaction value: $0
Accepted by SEC: 16 Jun 2021, 19:12
Role: Director
Next action: Open filing details

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .